- Home
- GCTK vs ADIL Comparison
GCTK vs ADIL Comparison
Compare GCTK & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTK
- ADIL
- Stock Information
- Founded
- GCTK 2001
- ADIL 2010
- Country
- GCTK United States
- ADIL United States
- Employees
- GCTK N/A
- ADIL N/A
- Industry
- GCTK Medical/Dental Instruments
- ADIL Biotechnology: Pharmaceutical Preparations
- Sector
- GCTK Health Care
- ADIL Health Care
- Exchange
- GCTK Nasdaq
- ADIL Nasdaq
- Market Cap
- GCTK 5.1M
- ADIL 4.8M
- IPO Year
- GCTK N/A
- ADIL 2018
- Fundamental
- Price
- GCTK $0.37
- ADIL $0.79
- Analyst Decision
- GCTK
- ADIL Strong Buy
- Analyst Count
- GCTK 0
- ADIL 1
- Target Price
- GCTK N/A
- ADIL $8.00
- AVG Volume (30 Days)
- GCTK 4.1M
- ADIL 172.8K
- Earning Date
- GCTK 03-27-2025
- ADIL 03-31-2025
- Dividend Yield
- GCTK N/A
- ADIL N/A
- EPS Growth
- GCTK N/A
- ADIL N/A
- EPS
- GCTK N/A
- ADIL N/A
- Revenue
- GCTK N/A
- ADIL N/A
- Revenue This Year
- GCTK N/A
- ADIL N/A
- Revenue Next Year
- GCTK N/A
- ADIL N/A
- P/E Ratio
- GCTK N/A
- ADIL N/A
- Revenue Growth
- GCTK N/A
- ADIL N/A
- 52 Week Low
- GCTK $0.36
- ADIL $0.72
- 52 Week High
- GCTK $99.00
- ADIL $4.17
- Technical
- Relative Strength Index (RSI)
- GCTK 26.08
- ADIL 40.52
- Support Level
- GCTK $0.49
- ADIL $0.76
- Resistance Level
- GCTK $0.68
- ADIL $0.85
- Average True Range (ATR)
- GCTK 0.20
- ADIL 0.05
- MACD
- GCTK 0.17
- ADIL 0.01
- Stochastic Oscillator
- GCTK 0.71
- ADIL 50.77
About GCTK GlucoTrack Inc.
GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.